Microbiota

Microbiota designates the diverse community of microorganisms including bacteria, archaea, fungi, viruses, and protozoans inhabiting specific body sites or environmental niches, with human microbiota predominantly residing in the gastrointestinal tract but also colonising skin, oral cavity, respiratory tract, and urogenital areas, collectively comprising trillions of microbial cells contributing metabolic, immunological, and protective functions profoundly influencing health and disease.

The biopharmaceutical industry increasingly recognises microbiota as therapeutic target, drug delivery consideration, and disease biomarker given accumulating evidence linking microbial dysbiosis to inflammatory bowel disease, obesity, diabetes, cardiovascular disease, cancer, neurological disorders, and immune dysfunction. Microbiome-modulating therapeutics employ probiotics, prebiotics, faecal microbiota transplantation, and next-generation approaches including defined bacterial consortia and engineered microbes. Drug development considers microbiota interactions influencing pharmacokinetics through drug metabolism and affecting efficacy through immune modulation. Oncology research reveals microbiota influences cancer development and immunotherapy responses, with specific bacterial species associated with improved checkpoint inhibitor efficacy. Antibiotic development must consider effects on commensal microbiota, with microbiome-sparing approaches minimising collateral damage. As mechanistic understanding deepens and engineered microbes gain sophistication delivering therapeutic molecules in situ, microbiota-based therapeutics continue emerging as novel treatment modalities.